Group 1 - The A-share CRO sector experienced a decline, with major companies like WuXi AppTec and Tigermed dropping over 7% [1] - Kanglong Chemical fell by more than 5%, while other firms such as Zhaoyan New Drug, Mediso, and Hengrui Medicine also saw declines [1]

Investment Rating - The industry investment rating is optimistic [2] Core Views - The report indicates a recovery in the industry, marking a turning point for allocation strategies [6] - The financial data and order trends suggest that the CXO sector has reached a fundamental turning point and is in a phase of continuous recovery [63] Summary by Sections Stock Price Review - Domestic performance shows a significant increase in the medical research outsourcing index, which rose by 60.41% from December 31, 2024, to September 4, 2025, outperforming the pharmaceutical and biotechnology index by 36.15 percentage points [4] - Internationally, there is a general upward revision of performance forecasts, with signs of demand recovery. Medpace showed the largest upward adjustment in its 2025 guidance [4][17] Financial Analysis - Growth: The year-over-year (YOY) revenue trend is improving, with the average YOY revenue growth for CXO companies reaching 8.2% in Q1 2025 and 11.6% in Q2 2025 [26] - Profitability: The average gross margin in Q2 2025 was 32.45%, showing a slight increase of 0.18 percentage points YOY. Some companies like Medpace and Boten Co. saw significant improvements in their margins [33] - Operational Efficiency: Inventory turnover improved from 1.56 in H1 2024 to 1.81 in H1 2025, indicating enhanced operational efficiency driven by increased capacity utilization [35] Thoughts and Outlook - PE/VC financing in the healthcare sector has stabilized at a low point, with a slight decline in absolute values for Q2 2025 compared to previous quarters, but ongoing improvements in global IPOs and business development transactions are expected to drive demand recovery [47] - IPO financing in the A-share and US markets has stabilized, while Hong Kong's market has seen a significant rebound, with HK IPO amounts reaching 20.7 billion HKD in 2025 [52] - The construction of new projects remains high, indicating optimistic expectations for capacity expansion among CXO companies, with a focus on new business areas such as ADCs and oligonucleotides [56] Investment Strategy - The report recommends investing in CDMO opportunities driven by the continued realization of commercial orders for small and large molecules, as well as clinical CRO opportunities supported by domestic innovation drug policies [63] - Key companies to watch include WuXi AppTec, Kelun Pharmaceutical, and others in the small molecule and large molecule CDMO sectors [63]

Core Viewpoint - The lawsuit involving Medisi and Hongxu Biotechnology has raised significant concerns in the CRO industry due to the stark contrast between the original contract value of 5.58 million yuan and the claimed compensation amount of approximately 159 million yuan, highlighting contract risk issues within the industry [2][4]. Group 1: Lawsuit Details - Medisi's subsidiary, Medisi Puya, is being sued by Hongxu Biotechnology for a total of approximately 159 million yuan, despite the original contract being worth only 5.58 million yuan [2][4]. - The lawsuit stems from a technical service contract signed on December 18, 2020, where Medisi Puya was tasked with conducting non-clinical safety evaluations for a biopharmaceutical product [4]. - Hongxu Biotechnology claims that Medisi Puya breached the contract, leading to the request for contract termination and five specific claims totaling around 159 million yuan [5]. Group 2: Claims and Responses - The five claims made by Hongxu Biotechnology include: 1. Termination of the technical service contract 2. Payment of liquidated damages based on previously paid amounts 3. Refund of service fees already paid 4. Compensation for various losses totaling 1.5 billion yuan 5. Coverage of litigation and preservation costs [5]. - Medisi has firmly rejected Hongxu's claims, asserting that it has complied with industry standards and fulfilled its contractual obligations, as evidenced by the approval of the clinical trial on December 14, 2023 [7][8]. Group 3: Industry Context - The CRO industry is experiencing increased contract disputes as competition intensifies, with Medisi not being the only company facing such legal challenges [9]. - As the biopharmaceutical sector matures, the competition among CROs is shifting from scale and price to quality, service, and risk management capabilities, making risk control a critical focus for all CRO companies [9].

Market Overview - The medical services sector increased by 1.22% on September 10, with Meidisi leading the gains [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Top Gainers in Medical Services - Meidisi (688202) closed at 75.91, up 14.36% with a trading volume of 172,900 shares and a turnover of 1.262 billion yuan [1] - Zhaoyan New Drug (603127) closed at 35.44, up 9.99% with a trading volume of 710,100 shares and a turnover of 2.481 billion yuan [1] - Bid Medicine (688073) closed at 67.40, up 7.72% with a trading volume of 23,600 shares and a turnover of 156 million yuan [1] - Other notable gainers include Pusens (301257), Nuohezhiyuan (688315), and Haoyuan Medicine (688131) with respective increases of 7.07%, 6.12%, and 5.81% [1] Market Capital Flow - The medical services sector saw a net inflow of 523 million yuan from institutional investors, while retail investors experienced a net outflow of 179 million yuan [2] - The top stocks by net inflow from institutional investors include Zhaoyan New Drug with 481 million yuan and YaoMingKangDe with 106 million yuan [3] Notable Decliners - Nanmo Biology (688265) decreased by 4.09% to 54.64 with a trading volume of 13,800 shares and a turnover of 76.751 million yuan [2] - Zihua Medicine (600721) fell by 3.25% to 9.82 with a trading volume of 479,100 shares and a turnover of 476 million yuan [2] - Other decliners include Haitai Biology (300683) and Huada Muyin (300676) with respective declines of 2.50% and 2.17% [2]

Market Overview - The Shanghai Composite Index closed at 3817.55 points, above the five-day moving average, with a change of 0.27% [1] - The total trading volume of A-shares reached 1,635.945 billion yuan [1] Stocks Performance - A total of 534 A-shares broke through the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Siquan New Materials (301489) with a deviation rate of 16.42% and a daily increase of 19.33% [1] - Jiayuan Technology (688388) with a deviation rate of 13.07% and a daily increase of 20.00% [1] - Meidisi (688202) with a deviation rate of 12.94% and a daily increase of 17.32% [1] Additional Stocks with Deviation Rates - Other stocks with notable performance include: - Keli Co., Ltd. (920088) with a deviation rate of 10.70% and a daily increase of 14.34% [1] - Lio Co., Ltd. (002131) with a deviation rate of 8.40% and a daily increase of 9.96% [1] - Shenghong Technology (300476) with a deviation rate of 7.81% and a daily increase of 13.89% [1] Summary of Selected Stocks - The following stocks also showed positive performance: - Yunyuan Energy (002053) with a deviation rate of 7.54% and a daily increase of 10.00% [1] - Fujian Jinshen (002679) with a deviation rate of 7.52% and a daily increase of 10.02% [1] - Dongfang Tongxin (600776) with a deviation rate of 6.92% and a daily increase of 9.98% [1]

证券代码：688202 证券简称：美迪西 公告编号：2025-057 上海美迪西生物医药股份有限公司 董事会薪酬与考核委员会 关于公司 2025 年限制性股票激励计划 首次授予激励对象名单的核查意见及公示情况说明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （二）核查方式 公司董事会薪酬与考核委员会对本激励计划首次授予激励对象的姓名、身份证 件、激励对象与公司、公司分公司或公司控股子公司签署的劳动合同或聘用合同、 激励对象在公司、公司分公司或公司控股子公司担任的职务等情况进行了核查。 二、董事会薪酬与考核委员会核查意见 上海美迪西生物医药股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召 开了第四届董事会第六次会议、第四届监事会第六次会议及第四届董事会薪酬与考 核委员会第二次会议，审议通过了《关于<上海美迪西生物医药股份有限公司 2025 年限制性股票激励计划（草案）>及其摘要的议案》《关于<上海美迪西生物医药 股份有限公司 2025 年限制性股票激励计划实施考核管理办法>的议案》等相关议案， 具体内 ...

Core Viewpoint - Shanghai Medicilon Biomedicine Co., Ltd. plans to terminate certain fundraising projects and redirect the remaining funds to new projects, permanently supplement working capital, and continue to store funds in a special account [1][27]. Group 1: Fundraising and Project Termination - The total amount raised by the company as of August 4, 2023, is RMB 1 billion, with a net amount of RMB 985.29 million after deducting fees [7][10]. - The terminated project is the "North Shanghai Biomedicine R&D Innovation Industrial Base Project," which was intended to enhance drug discovery capabilities but is no longer aligned with market demands [11][12]. - The remaining funds of RMB 289.90 million will be allocated as follows: RMB 40 million for increasing capital in MEDICILON USA CORP, RMB 160 million for working capital, and RMB 89.90 million will remain in the special account [12][13]. Group 2: New Project Overview - The new project involves establishing an "Overseas Marketing and R&D Center" in the U.S. to enhance the company's international presence and service capabilities [13][20]. - The project aims to leverage existing overseas sales and R&D teams to expand the company's market influence and improve customer service efficiency [13][19]. - The company has already established a 2,000 square meter R&D office in Boston, which will serve as a strategic hub for this initiative [20][22]. Group 3: Industry Context and Growth Potential - The global pharmaceutical market is expected to grow steadily, driven by increasing R&D investments, with global R&D spending projected to rise from USD 260.6 billion in 2023 to USD 359.2 billion by 2028, reflecting a CAGR of approximately 6.6% [16][17]. - The CRO (Contract Research Organization) industry is experiencing growth, with increasing demand for outsourced R&D services, which is expected to enhance the market penetration of CROs from 49.2% in 2023 to 58.2% by 2028 [20][21]. - The domestic CRO industry is evolving rapidly, with companies actively seeking to expand internationally and improve their service capabilities to meet global standards [17][22].

证券代码：688202 证券简称：美迪西 上海美迪西生物医药股份有限公司 2025 年第二次临时股东大会会议资料 二〇二五年九月 上海美迪西生物医药股份有限公司 2025 年第二次临时股东大会会议资料目录 | 2025 年第二次临时股东大会会议须知 1 | | --- | | 年第二次临时股东大会会议议程 4 2025 | | 议案一：关于部分募投项目终止并将剩余募集资金投入新项目、永久补充流动资金及继 | | 续存放在募集资金专户的议案 6 | | 议案二：关于取消公司监事会、修订《公司章程》并办理工商变更登记的议案 17 | | 议案三：关于修订和制定公司部分治理制度的议案 67 | | 议案四：关于《上海美迪西生物医药股份有限公司 2025 年限制性股票激励计划（草案）》 | | 及其摘要的议案 68 | | 议案五：关于《上海美迪西生物医药股份有限公司 2025 年限制性股票激励计划实施考 | | 核管理办法》的议案 69 | | 议案六：关于提请股东大会授权董事会办理公司股权激励计划相关事宜的议案 71 | 上海美迪西生物医药股份有限公司 2025 年第二次临时股东大会会议资料 上海美迪西生物医药股 ...

Core Viewpoint - The dispute between Medisi and its client Hongxu Bio over a technology service contract highlights tensions in the GLP-1 drug development sector, with potential implications for Medisi's business reputation and financial stability [1][3][7]. Group 1: Dispute Details - Medisi's subsidiary, Medisi Puya, is being sued by Hongxu Bio for breach of contract related to non-clinical safety evaluation studies for a biopharmaceutical project [1][3]. - The contract required Medisi Puya to complete four experimental projects within eight months and provide reports in both Chinese and English [1]. - Hongxu Bio claims that Medisi Puya failed to fulfill its contractual obligations, seeking contract termination and compensation for losses [1][3]. Group 2: Financial Implications - The lawsuit involves claims exceeding 1 billion yuan, including breach penalties and service fee refunds, which could significantly impact Medisi's financial health [7]. - Medisi reported a total revenue of 540 million yuan in the first half of the year, indicating that a successful lawsuit by Hongxu could lead to substantial financial losses for Medisi [7][9]. - Despite the lawsuit, Medisi's overall business operations remain normal, and the company is actively responding to the legal challenge [7]. Group 3: Company Performance - Medisi's revenue for the first half of the year increased by 3.64% year-on-year to 540 million yuan, with domestic revenue at 292 million yuan and overseas revenue growing by 31.08% to 248 million yuan [9]. - The company reported a net loss of approximately 12.9 million yuan, but this represents a significant reduction in losses compared to the previous year [9]. - Medisi has experienced a decline in revenue and profitability since its peak in 2022, with ongoing challenges in achieving sustainable profitability [8].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688202 证券简称：美迪西 公告编号：2025-056 上海美迪西生物医药股份有限公司 关于参加 2025 年半年度科创板创新药行业集体业绩 说明会的公告 本次投资者说明会以网络文字互动形式召开，公司将针对 2025 年半年度的 经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回答。 会议召开时间：2025 年 9 月 16 日（星期二）15:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 二、说明会召开的时间、地点 （一） 会议召开时间：2025 年 9 月 16 日（星期二）15:00-17:00 （二） 会议召开地点：上证路演中心（https://roadshow.sseinfo.com/） （三） 会议召开方式：上证路演中心网络文字 ...